Acadia Claims Success For Nuplazid In A Broader Psychosis Indication
The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.
You may also be interested in...
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.